SCHUMACHER
11-07-2014, 01:54 PM
Hi all, waiting for results on their tests as per below and if they are successful which i think they will be the money from funds will come in quick and the share price will be over 10c - moderate risk but in an industry that is worth billions. These goys know what they are doing so take a lok and form your own opinions . I'm in for a million shares - good luck as trials underway :)
Commencement of Human Clinical Study for an Oral Treatment for Osteoporosis
02 July 2014: Bone Medical Ltd (Bone Medical or the Company) is pleased to announce that it has commenced the planned human clinical study as announced to the ASX on 4 April 2014.
The study will compare Bone Medical’s potential oral treatment for osteoporosis, CaPTHymoneTM, against a commercially available injectable osteoporosis treatment, Forteo®.
Parathyroid hormone (“PTH”) is a naturally-occurring hormone that plays an important role in regulating bone formation. Bone Medical is developing an orally-delivered PTH formulation for the treatment of osteoporosis. An injectable PTH formulation, Forteo® is already approved and on the market for the treatment of osteoporosis. Forteo® reported sales in excess of US$1.2 billion in 2013. However, patient acceptance of this product is limited by the fact that it needs to be injected, and it is expected that an oral form will lead to a significant increase in market size.
The human clinical trial will primarily assess and compare PTH blood levels based on administering different dosage strengths of Bone Medical’s oral PTH formulation versus the injectable Forteo® PTH formulation. Each patient will receive three different oral PTH dosage strengths, Forteo®, or placebo in random order. The trial is an extension of a similar study conducted in 2012- 13 using lower oral PTH doses that showed evidence of biological activity, confirming absorption after oral administration.
A separate earlier study demonstrated the presence of PTH peptide fragments in the bloodstream after oral administration of the CaPTHymoneTM formulation. The current study’s aim is to confirm this finding, thus paving the way for further studies in the clinical development programme, looking at long-term change in bone growth, which will engage early industry partnering interest. If, at the same time, intact PTH peptides are detected in the blood, this could permit an even faster, simplified development plan for CaPTHymoneTM.
Registered Office: Ground Floor, 16 Ord Street, West Perth, WA, 6005 Ph: + 61 8 9482 0580 Fax: + 61 8 9482 0505

Commencement of Human Clinical Study for an Oral Treatment for Osteoporosis
02 July 2014: Bone Medical Ltd (Bone Medical or the Company) is pleased to announce that it has commenced the planned human clinical study as announced to the ASX on 4 April 2014.
The study will compare Bone Medical’s potential oral treatment for osteoporosis, CaPTHymoneTM, against a commercially available injectable osteoporosis treatment, Forteo®.
Parathyroid hormone (“PTH”) is a naturally-occurring hormone that plays an important role in regulating bone formation. Bone Medical is developing an orally-delivered PTH formulation for the treatment of osteoporosis. An injectable PTH formulation, Forteo® is already approved and on the market for the treatment of osteoporosis. Forteo® reported sales in excess of US$1.2 billion in 2013. However, patient acceptance of this product is limited by the fact that it needs to be injected, and it is expected that an oral form will lead to a significant increase in market size.
The human clinical trial will primarily assess and compare PTH blood levels based on administering different dosage strengths of Bone Medical’s oral PTH formulation versus the injectable Forteo® PTH formulation. Each patient will receive three different oral PTH dosage strengths, Forteo®, or placebo in random order. The trial is an extension of a similar study conducted in 2012- 13 using lower oral PTH doses that showed evidence of biological activity, confirming absorption after oral administration.
A separate earlier study demonstrated the presence of PTH peptide fragments in the bloodstream after oral administration of the CaPTHymoneTM formulation. The current study’s aim is to confirm this finding, thus paving the way for further studies in the clinical development programme, looking at long-term change in bone growth, which will engage early industry partnering interest. If, at the same time, intact PTH peptides are detected in the blood, this could permit an even faster, simplified development plan for CaPTHymoneTM.
Registered Office: Ground Floor, 16 Ord Street, West Perth, WA, 6005 Ph: + 61 8 9482 0580 Fax: + 61 8 9482 0505